Evidence map›Paper›PMID 30301470›Full record

ArticleBMC medicine2018

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Ines Stevic, Volkmar Müller, Karsten Weber, Peter A Fasching, Thomas Karn, Frederic Marmé, Christian Schem, Elmar Stickeler, Carsten Denkert, Marion van Mackelenbergh and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Platinum-based chemotherapy for early triple-negative breast cancer.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Enter sandman: how to tackle dormant breast cancer cells.Medical oncology (Northwood, London, England) · 2025
    Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ines StevicDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Volkmar MüllerDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Karsten WeberGBG Forschungs GmbH, Neu-Isenburg, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Thomas KarnUniversity Women's Hospital, Frankfurt, Germany.
Frederic MarméCenter for Gynecological Oncology at University Women's Hospital, Heidelberg, Germany.
Christian SchemMammazentrum Hamburg, Hamburg, Germany.
Elmar StickelerUniversitätsklinikum Aachen, Aachen, Germany.
Carsten DenkertCharite Berlin, Institute of Pathology and German Cancer Consortium (DKTK), Partner Site, Berlin, Germany.
Marion van MackelenberghUniversitätsklinikums Schleswig-Holstein Kiel, Kiel, Germany.
Christoph SalatHämatoonkologische Schwerpunktpraxis, Munich, Germany.
Andreas SchneeweissUniversitätsklinikum Heidelberg, Heidelberg, Germany.
Klaus PantelDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Sibylle LoiblGBG Forschungs GmbH, Neu-Isenburg, Germany.
Michael UntchHelios Kliniken Berlin-Buch, Berlin, Germany.
Heidi SchwarzenbachDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. h.schwarzenbach@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC).

methodsFirst, miRNA expression profiles were determined in exosomes derived from the plasma of 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based microRNA array card containing 384 different miRNAs. Forty-five miRNAs associated with different clinical parameters were then selected and mounted on microRNA array cards that served for the quantification of exosomal miRNAs in 435 BC patients before therapy and 20 healthy women. Confocal microscopy, Western blot, and ELISA were used for exosome characterization.

resultsQuantification of 45 exosomal miRNAs showed that compared with healthy women, 10 miRNAs in the entire cohort of BC patients, 13 in the subgroup of 211 HER2-positive BC, and 17 in the subgroup of 224 TNBC were significantly deregulated. Plasma levels of 18 exosomal miRNAs differed between HER2-positive and TNBC subtypes, and 9 miRNAs of them also differed from healthy women. Exosomal miRNAs were significantly associated with the clinicopathological and risk factors. In uni- and multivariate models, miR-155 (p = 0.002, p = 0.003, respectively) and miR-301 (p = 0.002, p = 0.001, respectively) best predicted pathological complete response (pCR).

conclusionOur findings show a network of deregulated exosomal miRNAs with specific expression patterns in exosomes of HER2-positive and TNBC patients that are also associated with clinicopathological parameters and pCR within each BC subtype.

Indexed as

Case-Control StudiesCohort StudiesErb-b2 Receptor Tyrosine KinasesExosomesFemaleHumansMicroRNAsMiddle AgedNeoadjuvant TherapyTriple Negative Breast NeoplasmsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMicroRNAsBreast cancerExosomesHER2-positiveMicroRNAsNeoadjuvant therapyPathological complete responseTriple negative

Identifiers

PMID30301470
PMCPMC6178264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.